+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Immunotherapy Drugs Market Research Report by Type (Cancer Vaccines, Checkpoint Inhibitors, and Immunomodulators), End-user, Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5336735
  • Report
  • April 2022
  • Region: Global
  • 194 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Cellectis
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
The Global Cancer Immunotherapy Drugs Market size was estimated at USD 168.93 billion in 2021, USD 190.60 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 13.00% to reach USD 351.80 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Cancer Immunotherapy Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market was studied across Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators, and Monoclonal Antibodies.
  • Based on End-user, the market was studied across Hospitals & Clinics.
  • Based on Application, the market was studied across Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, and Prostate Cancer.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cancer Immunotherapy Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Immunotherapy Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Immunotherapy Drugs Market, including Amgen Inc., AstraZeneca plc, Atara Biotherapeutics, Inc., Bayer AG, Bluebird bio, Inc., Bristol-Myers Squibb, Celldex Therapeutics, Cellectis, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Janssen Global Services, LLC, Juno Therapeutics, Merck & Co., Inc., NewLink Genetics Corporation, Novartis AG, Pfizer Inc., and Ziopharm Oncology, Inc..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Cancer Immunotherapy Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Immunotherapy Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Immunotherapy Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Immunotherapy Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Immunotherapy Drugs Market?
6. What is the market share of the leading vendors in the Global Cancer Immunotherapy Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer Immunotherapy Drugs Market?
Frequently Asked Questions about the Global Cancer Immunotherapy Drugs Market

What is the estimated value of the Global Cancer Immunotherapy Drugs Market?

The Global Cancer Immunotherapy Drugs Market was estimated to be valued at $168.9 Billion in 2021.

What is the growth rate of the Global Cancer Immunotherapy Drugs Market?

The growth rate of the Global Cancer Immunotherapy Drugs Market is 13.0%, with an estimated value of $351.8 Billion by 2027.

What is the forecasted size of the Global Cancer Immunotherapy Drugs Market?

The Global Cancer Immunotherapy Drugs Market is estimated to be worth $351.8 Billion by 2027.

Who are the key companies in the Global Cancer Immunotherapy Drugs Market?

Key companies in the Global Cancer Immunotherapy Drugs Market include Amgen Inc., AstraZeneca plc, Atara Biotherapeutics, Inc., Bayer AG, Bluebird bio, Inc., Bristol, Myers Squibb, Celldex Therapeutics and ELI Lilly and Company.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Cellectis
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in prevalence of cancer across the world
5.1.1.2. Growing adoption of immunotherapy over other treatments
5.1.1.3. Developments of bioinformatics tools and resources for cancer immunotherapy study
5.1.2. Restraints
5.1.2.1. Possibilities of adverse effects of the available therapies
5.1.3. Opportunities
5.1.3.1. Recent developments in immunotherapy technologies
5.1.3.2. Significant investment and funding for immunotherapy research
5.1.4. Challenges
5.1.4.1. High cost of therapy and unpredictable effectiveness of immuno-oncology agents
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Cancer Immunotherapy Drugs Market, by Type
6.1. Introduction
6.2. Cancer Vaccines
6.3. Checkpoint Inhibitors
6.4. Immunomodulators
6.5. Monoclonal Antibodies
7. Cancer Immunotherapy Drugs Market, by End-user
7.1. Introduction
7.2. Hospitals & Clinics
8. Cancer Immunotherapy Drugs Market, by Application
8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Head and Neck Cancer
8.5. Lung Cancer
8.6. Melanoma
8.7. Prostate Cancer
9. Americas Cancer Immunotherapy Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Immunotherapy Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Cancer Immunotherapy Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Amgen Inc.
13.2. AstraZeneca plc
13.3. Atara Biotherapeutics, Inc.
13.4. Bayer AG
13.5. Bluebird bio, Inc.
13.6. Bristol-Myers Squibb
13.7. Celldex Therapeutics
13.8. Cellectis
13.9. ELI Lilly and Company
13.10. F. Hoffmann-La Roche Ltd
13.11. Gilead Sciences, Inc.
13.12. GlaxoSmithKline plc
13.13. Incyte Corporation
13.14. Janssen Global Services, LLC
13.15. Juno Therapeutics
13.16. Merck & Co., Inc.
13.17. NewLink Genetics Corporation
13.18. Novartis AG
13.19. Pfizer Inc.
13.20. Ziopharm Oncology, Inc.
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: DYNAMICS
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2027
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2021 VS 2027 (USD BILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2027
FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, 2019-2027 (USD BILLION)
FIGURE 17. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 18. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 19. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD BILLION)
FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2027
FIGURE 21. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2019-2027 (USD BILLION)
FIGURE 22. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 23. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, 2019-2027 (USD BILLION)
FIGURE 24. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 25. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, 2019-2027 (USD BILLION)
FIGURE 26. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 27. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2019-2027 (USD BILLION)
FIGURE 28. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 29. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2019-2027 (USD BILLION)
FIGURE 30. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 31. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, 2019-2027 (USD BILLION)
FIGURE 32. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 33. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 34. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 35. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 36. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 37. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 38. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 39. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 40. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. INDONESIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. MALAYSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. PHILIPPINES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. SINGAPORE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. SOUTH KOREA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. TAIWAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. THAILAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 59. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 60. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 64. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 65. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 20. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 22. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2019-2027 (USD BILLION)
TABLE 25. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2019-2027 (USD BILLION)
TABLE 26. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 27. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY STATE, 2019-2027 (USD BILLION)
TABLE 28. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 30. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 31. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 32. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 33. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 34. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 36. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 37. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 38. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 39. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 41. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 42. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 43. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 44. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 46. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 47. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 48. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 49. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 51. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2019-2027 (USD BILLION)
TABLE 52. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 53. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY STATE, 2019-2027 (USD BILLION)
TABLE 54. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 56. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 57. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 58. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 59. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 61. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 62. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 63. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 64. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 65. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 66. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 67. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 68. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 69. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 70. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 71. INDONESIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 72. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 73. MALAYSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 74. PHILIPPINES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 75. SINGAPORE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 76. SOUTH KOREA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 77. TAIWAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 78. THAILAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 80. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 81. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 82. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 83. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 84. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 85. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 86. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 87. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 88. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 89. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 90. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 91. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: SCORES
TABLE 92. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: BUSINESS STRATEGY
TABLE 93. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: PRODUCT SATISFACTION
TABLE 94. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: RANKING
TABLE 95. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 96. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: MERGER & ACQUISITION
TABLE 97. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 98. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 99. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: INVESTMENT & FUNDING
TABLE 100. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 101. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • AstraZeneca plc
  • Atara Biotherapeutics, Inc.
  • Bayer AG
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb
  • Celldex Therapeutics
  • Cellectis
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Janssen Global Services, LLC
  • Juno Therapeutics
  • Merck & Co., Inc.
  • NewLink Genetics Corporation
  • Novartis AG
  • Pfizer Inc.
  • Ziopharm Oncology, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...